{"id":"probenecid-500-milligrams-mg","safety":{"commonSideEffects":[{"rate":null,"effect":"Gout flare (acute attack)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Nephrolithiasis (kidney stones)"}]},"_chembl":{"chemblId":"CHEMBL897","moleculeType":"Small molecule","molecularWeight":"285.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Probenecid is a uricosuric agent that blocks the URAT1 transporter in the proximal convoluted tubule of the kidney, preventing the reabsorption of filtered uric acid back into the bloodstream. By promoting urinary uric acid excretion, it reduces serum uric acid concentrations, thereby preventing gout attacks and uric acid crystal deposition in tissues. It also has secondary effects on the renal secretion of other organic anions.","oneSentence":"Probenecid inhibits the renal tubular reabsorption of uric acid, increasing urinary excretion and lowering serum uric acid levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:08.393Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic gout management and prevention of gout attacks"},{"name":"Hyperuricemia"}]},"trialDetails":[{"nctId":"NCT05903859","phase":"PHASE3","title":"Improvement of Reproductive Function in Men With Spinal Cord Injury (SCI)","status":"RECRUITING","sponsor":"University of Miami","startDate":"2024-01-18","conditions":"Infertility, Male","enrollment":90},{"nctId":"NCT03105986","phase":"PHASE1","title":"A Phase 1 Study to Evaluate the Effect of the Organic Anion Transporter Inhibitor Probenecid on the Pharmacokinetics of JNJ-64041575 in Healthy Adults","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2017-04-05","conditions":"Healthy","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Probenecid 500 Milligrams (mg)","genericName":"Probenecid 500 Milligrams (mg)","companyName":"University of Miami","companyId":"university-of-miami","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Probenecid inhibits the renal tubular reabsorption of uric acid, increasing urinary excretion and lowering serum uric acid levels. Used for Chronic gout management and prevention of gout attacks, Hyperuricemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}